Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial
Year: 2026
Type: article
Study design: Clinical Trial
Source: The Lancet Infectious Diseases
Authors: Frank Bähner, Saul N Faust, Leela R L Davies, Olga Blokhina, Donald M Brandon, William B Smith, Vengalil Krishna K Chatterjee, Hana Hassanin, Tara M Babu, Adam Zuiani, Susanne Steinhauser, Asaf Poran, Claire Brittain, Eric Mucker, Jay W Hooper, Robbert G van der Most, Pedro L Alonso, Özlem Türeci, Federico J Mensa, Uğur Şahin
Institutions: BioNTech (Germany), University Hospital Southampton NHS Foundation Trust, NIHR Southampton Biomedical Research Centre, University of Southampton, BioNTech (United States), Alliance for Multispecialty Research (United States), National Institute for Health and Care Research, NIHR Cambridge Biomedical Research Centre, University of Surrey, Royal Surrey NHS Foundation Trust, University of Washington, United States Army Medical Research Institute of Infectious Diseases, Helmholtz Institute for Translational Oncology Mainz
Language: English
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7163346389